GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » Other Financing

CARISMA Therapeutics (FRA:W2J) Other Financing : €-0.58 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Other Financing?

CARISMA Therapeutics's Other Financing for the three months ended in Dec. 2024 was €-0.31 Mil.

CARISMA Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.58 Mil.

CARISMA Therapeutics Other Financing Historical Data

The historical data trend for CARISMA Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Other Financing Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Other Financing
0.02 -0.32 -0.77 29.57 -0.59

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.35 -0.32 -0.30 -0.31

CARISMA Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Other Financing Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » Other Financing
Comparable Companies
MBRX SABS CLCS MTVA MRKR NXTC HOTH GLYC HCWB PHGE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CARM:USA
Address
3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
Website
https://www.carismatx.com
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics Headlines

No Headlines